Status:
COMPLETED
PD-1/PD-L1 Pathway Study on Septic Patients
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
National Natural Science Foundation of China
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Brief Summary
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.
Detailed Description
First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls. Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC ...
Eligibility Criteria
Inclusion
- patients who develop sepsis
Exclusion
- patients with cirrhosis or renal dysfunction
- patients with dyscrasia
- patients with autoimmunity diseases
- patients with severe cardiac and pulmonary diseases
- patients with hematological diseases
- patients with diabetes mellitus
- patients with malignant tumors
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01161745
Start Date
December 1 2008
End Date
April 1 2010
Last Update
July 14 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.